AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3587902 — intervention group
Group type: COMPARATOR
Intervention: Initial partial tumor resection
Number of subjects: 127
Study 3587902 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 127
Study 29606517 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01B HIV-1 vaccine candidate
Number of subjects: 231
Study 29606517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 27852717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 27852717 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 80
Study 24356715 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 60
Study 24356715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19673954 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placement protocol (4 weeks after tooth extraction)
Number of subjects: 20
Study 19673954 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement protocol (12 weeks after tooth extraction)
Number of subjects: 20
Study 19673954 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placement protocol
Number of subjects: 20
Study 19673954 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement protocol
Number of subjects: 20
Study 19673954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and delayed protocols
Number of subjects: 20
Study 20802351 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6244 (100 mg oral free-base suspension twice daily)
Number of subjects: 84
Study 20802351 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m2 intravenous once every 3 weeks)
Number of subjects: 84
Study 20802351 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6244
Number of subjects: 84
Study 20802351 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 84
Study 19054833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinell TTS 20 patch (single dose)
Number of subjects: 24
Study 19054833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinell TTS 20 patch (multiple doses over 4 days)
Number of subjects: 24
Study 15690307 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 0
Study 15690307 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate supplementation
Number of subjects: 0
Study 15690307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Protein and Carbohydrate)
Number of subjects: 0
Study 14646626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin at a dose of 150 mg/m2 and WR‐2721 at a dose of 910 mg/m2
Number of subjects: 94
Study 14646626 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone at a dose of 120 mg/m2
Number of subjects: 94
Study 14646626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with WR‐2721
Number of subjects: 94
Study 14646626 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 94
Study 10671837 — intervention group
Group type: EXPERIMENTAL
Intervention: Background infusion of 5 ml x h‐1 (Group B)
Number of subjects: 42
Study 10671837 — intervention group
Group type: COMPARATOR
Intervention: No background infusion (Group N)
Number of subjects: 42
Study 8813987 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoprosthesis (BE) with a 7F double-pigtail endoprosthesis and < 0.75 cm sphincterotomy
Number of subjects: 43
Study 8813987 — intervention group
Group type: COMPARATOR
Intervention: Duct clearance (DC) with standard 1.25-1.50 cm sphincterotomy and stone extraction by balloon or basket, with or without mechanical lithotripsy
Number of subjects: 43
Study 8813987 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoprosthesis (BE)
Number of subjects: 43
Study 8813987 — intervention group
Group type: COMPARATOR
Intervention: Duct clearance (DC)
Number of subjects: 43
Study 1594261 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aspirin/diethyl ether (ADE) mixture
Number of subjects: 45
Study 1594261 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin and diclofenac drug/ether mixtures
Number of subjects: 45
Study 6705752 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (add-on therapy)
Number of subjects: 0
Study 6705752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 30925733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate Extract (PE)
Number of subjects: 26
Study 30925733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 26
Study 28866294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian response adaptive randomization (BRAR) algorithms
Number of subjects: 0
Study 28866294 — intervention group
Group type: COMPARATOR
Intervention: Fixed equal allocation design
Number of subjects: 0
Study 28866294 — intervention group
Group type: EXPERIMENTAL
Intervention: Properly selected BRAR algorithm
Number of subjects: 0
Study 26044257 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of combined physical exercise training (EG)
Number of subjects: 57
Study 26044257 — intervention group
Group type: COMPARATOR
Intervention: No specifically orientated physical activity (CG)
Number of subjects: 57
Study 24300768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinorin
Number of subjects: 70
Study 24300768 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 21911866 — intervention group
Group type: COMPARATOR
Intervention: Synchronous arm cranking (SYN)
Number of subjects: 32
Study 21911866 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous arm cranking (ASY)
Number of subjects: 32
Study 19882589 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival regenerative factor-rich plasma (RFRP) for moderate burns
Number of subjects: 35
Study 19882589 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival regenerative factor-rich plasma (RFRP) for severe burns
Number of subjects: 35
Study 19882589 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival regenerative factor-rich plasma (RFRP)
Number of subjects: 35
Study 16731878 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT case management in addition to usual medical and nursing home care
Number of subjects: 62
Study 16731878 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study 14504005 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil 500 g cream
Number of subjects: 94
Study 14504005 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil 1000 g cream
Number of subjects: 94
Study 14504005 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil 1500 g cream
Number of subjects: 94
Study 14504005 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 94
Study 10348802 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose disulfiram
Number of subjects: 0
Study 10348802 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 0
Study 8547045 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) calculated according to body weight (0.6 mg/kg)
Number of subjects: 41
Study 8547045 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) calculated according to body surface area (25 mg/m2)
Number of subjects: 41
Study 8547045 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) doses of 40 or 50 mg based on body surface area
Number of subjects: 41
Study 1777376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine + Propranolol
Number of subjects: 2
Study 1777376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine + Atenolol
Number of subjects: 2
Study 7017074 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ointment from 95% ethanol extract of Lupinus termis seeds
Number of subjects: 0
Study 7017074 — intervention group
Group type: COMPARATOR
Intervention: 0.02% flumethasone pivalate ointment
Number of subjects: 0
Study 7017074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6519740 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet restricted in energy (fats and carbohydrates) but unrestricted in sodium (Group 1), n = 13
Number of subjects: 23
Study 6519740 — intervention group
Group type: COMPARATOR
Intervention: Diet restricted in energy and sodium (Group 2), n = 10
Number of subjects: 23
Study 30577819 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Intervention (n=30) received a Fitbit® Flex™ and four bi-weekly activity counselling sessions
Number of subjects: 61
Study 30577819 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention (n=31) received the same intervention two months later
Number of subjects: 61
Study 27566633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 553
Study 24580124 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention including tympanic effusion incision or catheterization, adenoidectomy and/or bilateral tonsillectomy for group 1 (0-6 years old) treated for approximately 2 months.
Number of subjects: 46
Study 24580124 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention including tympanic effusion incision or catheterization, adenoidectomy and/or bilateral tonsillectomy for group 2 (7-15 years old) treated for 10 months.
Number of subjects: 46
Study 22500821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegnivacogin 0.5 mg kg(‐1)
Number of subjects: 36
Study 22500821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegnivacogin 1.0 mg kg(‐1)
Number of subjects: 36
Study 22500821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegnivacogin 3.0 mg kg(‐1)
Number of subjects: 36
Study 22500821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegnivacogin 2.0 mg kg(‐1)
Number of subjects: 36
Study 22500821 — intervention group
Group type: COMPARATOR
Intervention: Anivamersen (single-dose)
Number of subjects: 36
Study 22500821 — intervention group
Group type: COMPARATOR
Intervention: Anivamersen (multidose)
Number of subjects: 36
Study 20399240 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP/Hib combination vaccine (3 doses at 3, 4, and 5 months)
Number of subjects: 720
Study 20399240 — intervention group
Group type: COMPARATOR
Intervention: Separate licensed DTaP vaccine and Hib conjugate vaccine (3 doses at 3, 4, and 5 months)
Number of subjects: 720
Study 19023839 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE curriculum
Number of subjects: 1160
Study 19023839 — intervention group
Group type: COMPARATOR
Intervention: Standard care (National Cancer Institute's Clearing the Air self‐help booklet)
Number of subjects: 1160
Study 16012942 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 232
Study 16012942 — intervention group
Group type: COMPARATOR
Intervention: Ethanol injection
Number of subjects: 232
Study 12696086 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency electromagnetic fields (RF EMF) exposure (900 MHz; SAR 1 W/kg) during sleep
Number of subjects: 2
Study 12696086 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency electromagnetic fields (RF EMF) exposure (900 MHz; SAR 1 W/kg) prior to sleep
Number of subjects: 2
Study 12696086 — intervention group
Group type: COMPARATOR
Intervention: Control condition with sham exposure
Number of subjects: 2
Study 12696086 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency electromagnetic fields (RF EMF) exposure during sleep
Number of subjects: 2
Study 10321402 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal health needs questionnaire
Number of subjects: 0
Study 10321402 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postal questionnaire)
Number of subjects: 0
Study 8806255 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with antiretroviral drugs
Number of subjects: 0
Study 8806255 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 0
Study 1988512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent attenuated (CR) vaccine
Number of subjects: 192
Study 1988512 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated (TI) vaccine
Number of subjects: 192
Study 1988512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 7158268 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of prilocaine and lidocaine)
Number of subjects: 60
Study 7158268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31022932 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (>2 kg, n = 74)
Number of subjects: 206
Study 31022932 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (>2 kg, n = 58)
Number of subjects: 206
Study 31022932 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stable (±2 kg, n = 74)
Number of subjects: 206
Study 30580260 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGN head injury guidelines (introduced in 2000)
Number of subjects: 571221
Study 30580260 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour ED target (introduced in 2004)
Number of subjects: 571221
Study 30580260 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGN head injury guidelines (introduced in 2009)
Number of subjects: 571221
Study 30580260 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging for head injuries (identified by guidelines)
Number of subjects: 571221
Study 27371185 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate total-body CT scanning
Number of subjects: 1403
Study 27371185 — intervention group
Group type: COMPARATOR
Intervention: Standard work-up
Number of subjects: 1403
Study 24555576 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE-5 inhibitors in adequately blinded trials
Number of subjects: 23877
Study 24555576 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE-5 inhibitors in inadequately blinded trials
Number of subjects: 23877
Study 24555576 — intervention group
Group type: COMPARATOR
Intervention: Placebo in adequately blinded trials
Number of subjects: 23877
Study 24555576 — intervention group
Group type: COMPARATOR
Intervention: Placebo in inadequately blinded trials
Number of subjects: 23877
Study 24555576 — intervention group
Group type: COMPARATOR
Intervention: Placebo groups with participants naïve to the intervention
Number of subjects: 23877
Study 24555576 — intervention group
Group type: COMPARATOR
Intervention: Placebo groups with participants having prior experience
Number of subjects: 23877
Study 24555576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups with participants naïve to the intervention
Number of subjects: 23877
Study 24555576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups with participants having prior experience
Number of subjects: 23877
Study 24555576 — intervention group
Group type: COMPARATOR
Intervention: Unblinding effect on placebo scores
Number of subjects: 23877
Study 24555576 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinding effect on intervention scores
Number of subjects: 23877
Study 22206712 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO)
Number of subjects: 92
Study 22206712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEV)
Number of subjects: 92
Study 22206712 — intervention group
Group type: COMPARATOR
Intervention: No volatile anesthesia (group O)
Number of subjects: 92
Study 20975577 — intervention group
Group type: EXPERIMENTAL
Intervention: e-diary
Number of subjects: 69
Study 20975577 — intervention group
Group type: COMPARATOR
Intervention: paper diary
Number of subjects: 69
Study 17279539 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 48
Study 17279539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 48
Study 17279539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16216094 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg dose of inhaler (powder inhaler)
Number of subjects: 10
Study 16216094 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg dose of inhaler (remaining powder)
Number of subjects: 10
Study 16216094 — intervention group
Group type: COMPARATOR
Intervention: Control (10% sucrose)
Number of subjects: 10
Study 16216094 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all inhalers)
Number of subjects: 10
Study 12603781 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hours TIB
Number of subjects: 66
Study 12603781 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 hours TIB
Number of subjects: 66
Study 12603781 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 hours TIB
Number of subjects: 66
Study 12603781 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 hours TIB
Number of subjects: 66
Study 12603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after 3 hours TIB
Number of subjects: 66
Study 12603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after 5 hours TIB
Number of subjects: 66
Study 12603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after 7 hours TIB
Number of subjects: 66
Study 12603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after 9 hours TIB
Number of subjects: 66
Study 10096691 — intervention group
Group type: EXPERIMENTAL
Intervention: Casewise estimator under random or complete ascertainment
Number of subjects: 0
Study 10096691 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairwise estimator under random or complete ascertainment
Number of subjects: 0
Study 10096691 — intervention group
Group type: EXPERIMENTAL
Intervention: Casewise estimator under incomplete ascertainment
Number of subjects: 0
Study 10096691 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairwise estimator under incomplete ascertainment
Number of subjects: 0
Study 10096691 — intervention group
Group type: EXPERIMENTAL
Intervention: Probandwise estimator under incomplete ascertainment
Number of subjects: 0
Study 7553006 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 47
Study 7553006 — intervention group
Group type: COMPARATOR
Intervention: Open release
Number of subjects: 47
Study 7553006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 2150105 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (first- or second-generation cephalosporins)
Number of subjects: 17
Study 2150105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2150105 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 17
Study 6941373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined injection of 3.0 mg/kg cimetidine and 0.3 mg/kg pirenzepine
Number of subjects: 13
Study 6941373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined injection of 1.5 mg/kg cimetidine, 0.075 and 0.15 mg/kg pirenzepine
Number of subjects: 13
Study 6941373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31286732 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical needling therapy of I-Ching; treatment at 1 PM to 3 PM, once a day for 20 days.
Number of subjects: 48
Study 31286732 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment of western medicine combined with TCM decoction; control group.
Number of subjects: 48
Study 26756171 — intervention group
Group type: EXPERIMENTAL
Intervention: 200U onabotulinum toxin A (onaBoNTA)
Number of subjects: 122
Study 25769541 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide and low-dose dexamethasone
Number of subjects: 0
Study 25769541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed cycles of lenalidomide and low-dose dexamethasone for 18 months
Number of subjects: 0
Study 25769541 — intervention group
Group type: COMPARATOR
Intervention: Fixed cycles of melphalan, prednisone, thalidomide for 18 months
Number of subjects: 0
Study 23532145 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm environment (33 °C)
Number of subjects: 12
Study 23532145 — intervention group
Group type: COMPARATOR
Intervention: Cold environment (7 °C)
Number of subjects: 12
Study 23532145 — intervention group
Group type: COMPARATOR
Intervention: Room temperature environment (20 °C)
Number of subjects: 12
Study 21500011 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (three times weekly)
Number of subjects: 229
Study 21500011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental activity (three times weekly)
Number of subjects: 229
Study 21500011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence (time spent on course attendance)
Number of subjects: 229
Study 21500011 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity mode (physical vs. mental)
Number of subjects: 229
Study 18387342 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Scale of Morningness (CSM)
Number of subjects: 456
Study 18387342 — intervention group
Group type: COMPARATOR
Intervention: Morningness‐Eveningness Questionnaire (MEQ)
Number of subjects: 456
Study 18387342 — intervention group
Group type: EXPERIMENTAL
Intervention: CSM and MEQ
Number of subjects: 456
Study 18387342 — intervention group
Group type: EXPERIMENTAL
Intervention: CSM
Number of subjects: 456
Study 18387342 — intervention group
Group type: COMPARATOR
Intervention: MEQ
Number of subjects: 456
Study 18387342 — intervention group
Group type: EXPERIMENTAL
Intervention: T-scores (mean of 50 and standard deviation of 10)
Number of subjects: 456
Study 16965431 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment twice daily
Number of subjects: 106
Study 16965431 — intervention group
Group type: COMPARATOR
Intervention: Dithranol cream once daily
Number of subjects: 106
Study 14984440 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone (60 mg)
Number of subjects: 24
Study 14984440 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (400 mg)
Number of subjects: 24
Study 14984440 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 24
Study 10701382 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiting nurse group
Number of subjects: 142
Study 10701382 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 142
Study 9342783 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT; 3 mg)
Number of subjects: 6
Study 9342783 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT; 9 mg)
Number of subjects: 6